| Day 1, Thursday, May 15th | |
|---|---|
| 08:15-08:30 | Welcome Coffee |
| 08:30-08:50 | COMy 2025 kick-off: Welcome by the Congress Co-Chairs |
| 08:50-10:20 | Session 1: Advances in biology I |
| Moderators: Eileen Boyle, USA; Paola Neri, Canada | |
| 08:50-09:05 | WGS: Samur Mehmet, USA |
| 09:05-09:20 | Clonal diversity: Joaquín Martínez López, Spain |
| 09:20-09:35 | Circulating tumor cells and DNA: Andrew Spencer, Australia |
| 09:35-09:50 | sBCMA and non-T cell factors: Marc Raab, Germany |
| 09:50-10:05 | Mass spectrometry: Noemi Puig, Spain |
| 10:05-10:20 | Discussion: All session faculty and Nizar Bahlis, Canada |
| 10:20-11:20 | Session 2: IMS Session |
| Moderators: Philippe Moreau, France; Nikhil Munshi, USA | |
| 10:20-10:40 | Does adaptation in MM: María-Victoria Mateos, Spain |
| 10:40-11:00 | Real-world evidence vs pivotal trials for approval: Philippe Moreau, France |
| 11:00-11:20 | Discussion |
| 11:20-11:40 | Coffee Break |
| 11:40-13:10 | Session 3: How do I assess? |
| Moderators: Joan Bladé, Spain; Heinz Ludwig, Austria | |
| 11:40-11:55 | AI individualized risk classifier: Francesco Maura, USA |
| 11:55-12:10 | Disease response: Shaji Kumar, USA |
| 12:10-12:25 | Imaging: Elena Zamagni, Italy |
| 12:25-12:40 | Disease risk: Jill Corre, France |
| 12:40-12:55 | From detection to decision: the status of MGUS screening: Sigurdur Kristinsson, Iceland |
| 12:55-13:10 | Discussion: All session faculty and Paola Neri, Canada, Enrique Ocio, Spain |
| 13:10-13:40 | Lunch Break |
| 13:40-15:10 | Opposite sides of the spectrum: individualising treatment from the fittest to the frailest in NDMM Industry-supported Lunch Symposium |
| 15:10-15:20 | Technical Break |
| 15:20-16:20 | Session 4: Advances in biology II |
| Moderators: Malin Hultcrantz, USA; Michael O’Dwyer, Ireland | |
| 15:20-15:35 | Protein degraders: Robert Orlowski, USA |
| 15:35-15:50 | The unanswered science of myeloma: Keith Stewart, Canada |
| 15:50-16:05 | Next generation CAR constructs: Noopur Raje, USA |
| 16:05-16:20 | Discussion: All session faculty and Faith Davies, USA |
| 16:20-16:40 | Coffee Break |
| 16:40-18:10 | Unmet Needs in Relapsed/Refractory Multiple Myeloma: Considering a BCMA-Directed Bispecific Industry-supported Afternoon Symposium |
| 18:10-18:20 | Technical Break |
| 18:20-19:00 | Session 5: Plenary lectures I |
| Moderators: Gareth Morgan, USA; Charlotte Pawlyn, UK | |
| 18:20-18:40 | From Thalidomide to CelMods: a clinical journey: Meletios Dimopoulos, Greece |
| 18:40-19:00 | Genomics to personalize therapy: Nikhil Munshi, USA |
| 19:00-19:30 | Session 6: The COMy Debate: treatment of smoldering myeloma |
| Moderators: María-Victoria Mateos, Spain; Philippe Moreau, France | |
| 19:00-19:10 | YES: Irene Ghobrial, USA |
| 19:10-19:20 | NO: Hervé Avet-Loiseau, France |
| 19:20-19:30 | Discussion: All session faculty and Claudio Cerchione, Italy, Karthik Ramasamy, UK |
| Day 2, Friday, May 16th | |
|---|---|
| 07:30-08:15 | The Trinity – The balance of Safety, Efficacy, and Quality of Life in TCR RRMM treatment Industry-supported Breakfast Symposium |
| 08:15-08:25 | Technical Break |
| 08:25-09:35 | Session 7: How do I treat? Part I |
| Moderators: Thierry Facon, France; Francesca Gay, Italy | |
| 08:25-08:40 | Transplant-eligible patients: Aurore Perrot, France |
| 08:40-08:55 | Elderly patients: Sonja Zweegman, Netherlands |
| 08:55-09:10 | High-risk disease: Cyrille Touzeau, France |
| 09:10-09:25 | Amyloidosis: Suzanne Lentzsch, USA |
| 09:25-09:35 | Discussion: All session faculty and Martin Kaiser, UK, Alessandra Larocca, Italy |
| 09:35-09:55 | Coffee Break |
| 09:55-11:25 | Unlocking the future of T cell therapies: advancing innovation and optimising impact Industry-supported Morning Symposium |
| 11:25-11:35 | Technical Break |
| 11:35-12:20 | Session 8 |
| Moderators: | |
| 11:35-11:50 | TBA |
| 11:50-12:05 | TBA |
| 12:05-12:20 | Discussion |
| 12:20-12:50 | Lunch Break |
| 12:50-14:20 | A puzzle in progress: Piecing together clinical trial data in NDMM Industry-supported Lunch Symposium |
| 14:20-14:30 | Technical Break |
| 14:30-15:15 | Session 9: Next generation CAR-T cells |
| Moderators: Doris Hansen, USA; Mohamad Mohty, France | |
| 14:30-14:45 | Why do we need newer CAR-T cell constructs? Salomon Manier, France |
| 14:45-15:00 | Results of the D-Domain BCMA-directed CAR-T construct: Binod Dhakal, USA |
| 15:00-15:15 | Discussion |
| 15:15-16:00 | Session 10: Plenary lectures II |
| Moderators: Bertrand Arnulf, France; Yael Cohen, Israel | |
| 15:15-15:30 | The Academic CAR-T cells experience: Carlos Fernández de Larrea, Spain |
| 15:30-15:45 | Antigenic escape with T cell redirecting immunotherapies: Nizar Bahlis, Canada |
| 15:45-16:00 | Discussion: All session faculty and Javier de la Rubia, Spain, Doris Hansen, USA |
| 16:00-16:20 | Coffee Break |
| 16:20-17:50 | Innovations in Relapsed Refractory Multiple Myeloma Care: Debating the Future of Treatment Strategies Industry-supported Afternoon Symposium |
| 17:50-18:00 | Technical Break |
| 18:00-19:00 | Session 11: Treatment of relapsed/refractory disease |
| Moderators: Roman Hajek, Czech Republic; Thomas Martin, USA | |
| 18:00-18:15 | Management of patients after 1 prior line of therapy: María-Victoria Mateos, Spain |
| 18:15-18:30 | Management of patients triple class refractory with CAR-T cells: Paula Rodríguez-Otero, Spain |
| 18:30-18:45 | Management of patients triple class refractory with bispecifics: Saad Usmani, USA |
| 18:45-19:00 | Discussion: All session faculty and Hermann Einsele, Germany, Cesar Rodriguez, USA |
| 19:00-19:30 | COMy Award Ceremony |
| Presented by the Congress Co-Chairs | |
| Day 3, Saturday, May 17th | |
|---|---|
| 08:15-08:30 | Good-Morning Coffee |
| 08:30-10:20 | Session 12: The ideal trial on the road to achieve the best outcome for patients |
| Moderators: Jean-Luc Harousseau, France; Jesús San Miguel, Spain | |
| 08:30-08:45 | A US perspective: Sagar Lonial, USA |
| 08:45-09:00 | EMN perspective: Pieter Sonneveld, Netherlands |
| 09:00-09:15 | UK perspective: Kwee Yong, UK |
| 09:15-09:30 | IFM perspective in young patients: Philippe Moreau, France |
| 09:30-09:45 | IFM and Spanish perspective in elderly patients: Salomon Manier, France |
| 09:45-10:00 | German perspective: Hartmut Goldschmidt, Germany |
| 10:00-10:20 | Discussion |
| 10:20-10:35 | Coffee Break continued … |
| 10:35-11:50 | Clinical Application of clonoSEQ Testing in MM Industry-supported Morning Symposium |
| 11:50-12:00 | Technical Break |
| 12:00-12:45 | Session 13: Hot topics |
| Moderators: Jean El Cheikh, Lebanon; Fernando Leal da Costa, Portugal | |
| 12:00-12:15 | Fixed duration vs. continuous maintenance therapy: Paul Richardson, USA |
| 12:15-12:30 | Maintenance therapy after ASCT: Xavier Leleu, France |
| 12:30-12:45 | Discussion: All session faculty and Malin Hultcrantz, USA; Roberto Mina, Italy |
| 12:45-13:15 | Lunch Break |
| 13:15-14:45 | Breaking barriers in myeloma: exploring the potential of antibody drug conjugates Industry-supported Lunch Symposium |
| 14:45-14:55 | Technical Break |
| 14:55-16:10 | Session 14: How do I treat? Part II |
| Moderators: Michel Delforge, Belgium; Albert Oriol, Spain | |
| 14:55-15:10 | Extra-medullary plasmacytoma: Meral Beksaç, Turkey |
| 15:10-15:25 | Patients under dialysis: Florent Malard, France |
| 15:25-15:40 | Bone disease: Evangelos Terpos, Greece |
| 15:40-15:55 | Waldenstrom disease: Steven Treon, USA |
| 15:55-16:10 | Discussion: All session faculty and Rafat Abonour, USA, Laura Rosiñol Dachs, Spain |
| 16:10-16:30 | Coffee Break |
| 16:30-17:15 | Session 15: Treatment of advanced relapse: beyond immunotherapy |
| Chairs: Mohamad Mohty, France; Hans Salwender, Germany | |
| 16:30-16:45 | The US experience: Joshua Richter, USA |
| 16:45-17:00 | The EU perspective: Claudio Cerchione, Italy |
| 17:00-17:15 | Discussion |
| 17:15-18:25 | Session 16: IACH special session |
| Moderator: Mohamad Mohty, France | |
| 17:15-17:30 | Introduction to the IACH Multiple Myeloma Academy: Mohamad Mohty, France |
| 17:30-17:50 | AI for doctors: the Why, the How and the Wow: Audelia Eshel-Fuhrer, Israel |
| 17:50-18:00 | Q&A |
| 18:00-18:15 | TBA |
| 18:15-18:25 | Q&A |
| 18:25-19:20 | Session 17: Keynote lectures |
| Moderators: Vania Hungria, Brazil; Noor Moukalled, Lebanon | |
| 18:25-18:45 | Affordable therapy algorithm: Vincent Rajkumar, USA |
| 18:45-19:05 | The future of myeloma therapy: Kenneth Anderson, USA |
| 19:05-19:20 | Discussion |
| 19:20-19:30 | COMy In-Person Conclusions by the Congress Co-Chairs |
| Day 4, Sunday, May 18th – ONLINE ONLY | |
|---|---|
| 10:00-11:30 | Multiple Myeloma communications I |
| Moderators: TBA | |
| 10:00-10:10 | Chromoanagenesis, a subtype of genome chaos, in multiple myeloma: integrating clinical data with optical genomic mapping: Christine Ye, USA |
| 10:10-10:20 | Extramedullary myeloma is genomically complex and characterized by near-universal MAPK pathway alterations: Saurabh Zanwar, USA |
| 10:20-10:30 | Linvoseltamab in patients with relapsed/refractory multiple myeloma (RRMM): longer follow-up and selected high-risk subgroup analyses of the LINKER-MM1 study: Mansi R Shah, USA |
| 10:30-10:40 | Modeling long-term progression-free survival in transplant-eligible (TE) and transplant-ineligible (TIE) newly diagnosed multiple myeloma (NDMM) treated with daratumumab, bortezomib, lenalidomide, and dexamethasone (DVRd): Pieter Sonneveld, Netherlands |
| 10:40-10:50 | Prospective functional bone disease evaluation of newly diagnosed multiple myeloma with combined use of (18)F-FDG-PET/CT and whole-body diffusion weighted magnetic resonance: Marco Talarico, Italy |
| 10:50-11:00 | Talquetamab (TAL) + teclistamab (TEC) in patients with triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM): updated phase 1b results from REDIRECTT-1 with >1 year of follow-up: Albert Oriol, Spain |
| 11:00-11:10 | Talquetamab (TAL), a GPRC5D×CD3 bispecific antibody (BsAb), in combination with daratumumab (D) and lenalidomide (R) in patients with newly diagnosed multiple myeloma (NDMM): safety and efficacy results from the phase 1b MONUMENTAL-2 study: Aurore Perrot, France |
| 11:10-11:30 | Discussion |
| Break | |
| 11:40-12:45 | Multiple Myeloma communications II |
| Moderators: TBA | |
| 11:40-11:50 | Cevostamab in combination with pomalidomide and dexamethasone in patients with relapsed/ refractory multiple myeloma (RRMM): updated phase i safety run-in results from the CAMMA 1 study Andrew Spencer, Canada |
| 11:50-12:00 | Effectiveness of bridging therapy corresponds to improved outcomes after receiving car-T therapy: phase 3 CARTITUDE-4 study of patients with relapsed, lenalidomide-refractory multiple myeloma: Xavier Leleu, France |
| 12:00-12:10 | MAGNETISMM-3: long-term update and outcomes of less frequent dosing of elranatamab in relapsed/refractory multiple myeloma (RRMM): TBA |
| 12:10-12:20 | Overall survival (OS) with ciltacabtagene autoleucel (CILTA-CEL) versus standard of care (SOC) in lenalidomide (LEN)-refractory multiple myeloma (MM): phase 3 CARTITUDE-4 study update: Cyrille Touzeau, France |
| 12:20-12:30 | Phase 1, first in-human, dose escalation study of ISB 2001, a BCMAxCD38xCD3 targeting trispecific antibody in patients with relapsed/refractory multiple myeloma (RRMM): Amit Knot, Australia |
| 12:30-12:45 | Discussion |
| Conclusion and see you next year! | |
